Lipid Lowering Effects of Iodothyronines: In Vivo and in Vitro Studies on Rat Liver

Overview

Journal World J Hepatol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 May 7

PMID 24799985

Citations 9

Authors

Laura Vergani

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is emerging as one of the most common liver diseases, leading to the increasing interest for new therapeutic approaches for its treatment. NAFLD primarily depends on a hypercaloric and/or unbalanced diet leading to overweight and obesity. The liver, in fact, plays a central role in lipid metabolism by importing free fatty acids from the blood and synthesizing, storing, oxidizing and exporting lipids. Furthermore, the liver is the target for the thyroid hormones, thyroxine (T4) and 3,3',5-triiodo-L-thyronine (T3), that stimulate the basal metabolic rate and lead to body weight loss. In the last decade, other iodothyronines have been shown to possess biological relevance and play some thyromimetic activities; in particular, 3,5-diiodo-L-thyronine (T2) gained large interest. The global effect of iodothyronines on liver lipid metabolism results from the balance between direct and indirect actions on the hepatocyte, leading to stimulation of lipid synthesis, oxidation and autophagy. In this review, the results so far obtained on both in vivo and in vitro models of hepatosteatosis are summarized in order to obtain an updated picture of the lipid-lowering effects of iodothyronines on mammalian liver.

Citing Articles

Unraveling the metabolic activities of bioactive compounds on cellular models of hepatosteatosis and adipogenesis through docking analysis with PPARs.

Diab F, Zbeeb H, Zeaiter L, Baldini F, Pagano A, Minicozzi V Sci Rep. 2024; 14(1):28196.

PMID: 39548141 PMC: 11568224. DOI: 10.1038/s41598-024-78374-7.

Comparative effects of 3,5-diiodo-L-thyronine and 3,5,3'-triiodo-L-thyronine on mitochondrial damage and cGAS/STING-driven inflammation in liver of hypothyroid rats.

Giacco A, Petito G, Silvestri E, Scopigno N, Vigliotti M, Mercurio G Front Endocrinol (Lausanne). 2024; 15:1432819.

PMID: 39301315 PMC: 11410700. DOI: 10.3389/fendo.2024.1432819.

Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand.

Gor R, Siddiqui N, Wijeratne Fernando R, Sreekantan Nair A, Illango J, Malik M Cureus. 2021; 13(5):e14858.

PMID: 34104598 PMC: 8174393. DOI: 10.7759/cureus.14858.

Direct effects of thyroid hormones on hepatic lipid metabolism.

Sinha R, Singh B, Yen P Nat Rev Endocrinol. 2018; 14(5):259-269.

PMID: 29472712 PMC: 6013028. DOI: 10.1038/nrendo.2018.10.

The Nutraceutic Silybin Counteracts Excess Lipid Accumulation and Ongoing Oxidative Stress in an Model of Non-Alcoholic Fatty Liver Disease Progression.

Vecchione G, Grasselli E, Cioffi F, Baldini F, Oliveira P, Sardao V Front Nutr. 2017; 4:42.

PMID: 28971098 PMC: 5609553. DOI: 10.3389/fnut.2017.00042.

References

Mirza M . Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol. 2011; 2011:592404. PMC: 3168494. DOI: 10.5402/2011/592404. View

Yehuda-Shnaidman E, Kalderon B, Azazmeh N, Bar-Tana J . Gating of the mitochondrial permeability transition pore by thyroid hormone. FASEB J. 2009; 24(1):93-104. DOI: 10.1096/fj.09-133538. View

Grasselli E, Voci A, Canesi L, Goglia F, Ravera S, Panfoli I . Non-receptor-mediated actions are responsible for the lipid-lowering effects of iodothyronines in FaO rat hepatoma cells. J Endocrinol. 2011; 210(1):59-69. DOI: 10.1530/JOE-11-0074. View

Davis P, Davis F, Cody V . Membrane receptors mediating thyroid hormone action. Trends Endocrinol Metab. 2005; 16(9):429-35. DOI: 10.1016/j.tem.2005.09.007. View

Hummerich H, Soboll S . Rapid stimulation of calcium uptake into rat liver by L-tri-iodothyronine. Biochem J. 1989; 258(2):363-7. PMC: 1138370. DOI: 10.1042/bj2580363. View

Bradbury M . Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol. 2006; 290(2):G194-8. DOI: 10.1152/ajpgi.00413.2005. View

Arnold S, Goglia F, KADENBACH B . 3,5-Diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of respiration by ATP. Eur J Biochem. 1998; 252(2):325-30. DOI: 10.1046/j.1432-1327.1998.2520325.x. View

Grasselli E, Voci A, Demori I, Canesi L, De Matteis R, Goglia F . 3,5-Diiodo-L-thyronine modulates the expression of genes of lipid metabolism in a rat model of fatty liver. J Endocrinol. 2011; 212(2):149-58. DOI: 10.1530/JOE-11-0288. View

Kanuri G, Bergheim I . In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci. 2013; 14(6):11963-80. PMC: 3709766. DOI: 10.3390/ijms140611963. View

10.

Plow E, Haas T, Zhang L, Loftus J, Smith J . Ligand binding to integrins. J Biol Chem. 2000; 275(29):21785-8. DOI: 10.1074/jbc.R000003200. View

11.

Everett L, Galli A, Crabb D . The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver. 2000; 20(3):191-9. DOI: 10.1034/j.1600-0676.2000.020003191.x. View

12.

Hulbert A . Thyroid hormones and their effects: a new perspective. Biol Rev Camb Philos Soc. 2000; 75(4):519-631. DOI: 10.1017/s146479310000556x. View

13.

Bickel P, Tansey J, Welte M . PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim Biophys Acta. 2009; 1791(6):419-40. PMC: 2782626. DOI: 10.1016/j.bbalip.2009.04.002. View

14.

Li Z, Berk M, McIntyre T, Feldstein A . Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem. 2009; 284(9):5637-44. PMC: 2645822. DOI: 10.1074/jbc.M807616200. View

15.

Musso G, Gambino R, Cassader M . Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2008; 48(1):1-26. DOI: 10.1016/j.plipres.2008.08.001. View

16.

Horst C, Rokos H, Seitz H . Rapid stimulation of hepatic oxygen consumption by 3,5-di-iodo-L-thyronine. Biochem J. 1989; 261(3):945-50. PMC: 1138920. DOI: 10.1042/bj2610945. View

17.

Gomez-Lechon M, Donato M, Martinez-Romero A, Jimenez N, Castell J, OConnor J . A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact. 2006; 165(2):106-16. DOI: 10.1016/j.cbi.2006.11.004. View

18.

Shih A, Zhang S, Cao H, Tang H, Davis F, Davis P . Disparate effects of thyroid hormone on actions of epidermal growth factor and transforming growth factor-alpha are mediated by 3',5'-cyclic adenosine 5'-monophosphate-dependent protein kinase II. Endocrinology. 2003; 145(4):1708-17. DOI: 10.1210/en.2003-0742. View

19.

Reddy J, Rao M . Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol. 2006; 290(5):G852-8. DOI: 10.1152/ajpgi.00521.2005. View

20.

Weinberger C, Thompson C, Ong E, Lebo R, Gruol D, Evans R . The c-erb-A gene encodes a thyroid hormone receptor. Nature. 1986; 324(6098):641-6. DOI: 10.1038/324641a0. View